Piper Jaffray Upgrades Genomic Health, Downgrades BD
January 22, 2010
Piper Jaffray Upgrades Genomic Health, Downgrades BD
The investment bank maintained its 12-month price targets on the respective stocks. It said that Genomic Health was trading at an "attractive entry point."
Full-text access for registered users only.
Existing users login here.
New to GenomeWeb? Register here quickly for free access.
New to GenomeWeb? Register here quickly for free access.
Related Stories
- Genomic Health Q2 Revenues Improve 13 Percent
August 9, 2012 / GenomeWeb Daily News - AMA Proposes New Coding Criteria for Multi-Analyte Algorithm-Based Tests
November 9, 2011 / Pharmacogenomics Reporter - Investment Firm Jefferies Resumes Coverage on Eight MDx, Genetic Testing, Tools Firms
March 11, 2011 / GenomeWeb Daily News - Genomic Health Reports 19 Percent Revenue Growth for Q4, FY 2010
February 9, 2011 / GenomeWeb Daily News - Mizuho Securities Initiates Coverage on MDx Firms
October 21, 2010 / GenomeWeb Daily News